Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IC 43

Drug Profile

IC 43

Alternative Names: IC-43; OprF-OprI vaccine - Valneva; PE-001; PE-002; Pseudomonas aeruginosa vaccine - Valneva; VLA 43

Latest Information Update: 15 Sep 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Valneva
  • Class Antibacterials; Pseudomonas vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pseudomonal infections

Most Recent Events

  • 31 Aug 2016 Discontinued - Phase-II/III for Pseudomonal infections (Prevention) in Czech Republic, Spain, Germany, Belgium, Hungary and Austria (IM) because phase II/III trial results did not confirm a positive vaccine effect
  • 21 Mar 2016 Valneva plans a phase III trial for Pseudomonal infections
  • 01 Dec 2015 Valneva completes a phase II/III trial in Pseudomonal infections in Austria, Belgium, Czech Republic, Germany, Hungary and Spain (IM) (NCT01563263)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top